evidence: Many of the initial clinical studies with COVID-19 vaccines have included a small number of people living with HIV (PLHIV) in their trials. Despite limited data, available information from those studies suggests that current WHO recommended COVID-19 vaccines are safe for PLHIV. The currently available COVID-19 vaccine products are not live vaccines but include modified viral proteins or genetic material from SARS-CoV-2 which cannot replicate or cause changes to human genes. More recent observational studies have further evaluated the safety of COVID-19 vaccines in this population and didn’t find any evidence of a higher rate of unusual side effects after vaccination when compared with general population. In addition, no pharmacological interactions have been reported between COVID-19 vaccines and antiretroviral medications (ARV) which [...] Currently approved COVID-19 vaccines are safe and effective in most PLHIV, with significant reduction in the risk of severe COVID-19 disease or death when the standard regimen (currently 1 or 2 doses of the approved COVID-19 vaccine depending on the product) is fully taken as recommended. However, there is a growing evidence of a suboptimal immune response to the standard course of COVID-19 vaccination in people with moderate to severe immunodeficiency, including those with advanced HIV disease, lower CD4 T-cell counts, or unsuppressed viral load.